e-learning
resources
London 2016
Tuesday, 06.09.2016
Mixed-up imaging of various chest diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up
Öner Balbay (Duzce, Turkey), Zeynep Burcin Yilmaz, Peri Meram Arbak, Tugçe Pasin, Esma Uslu, Ege Güleç Balbay, Öner Balbay
Source:
International Congress 2016 – Mixed-up imaging of various chest diseases
Session:
Mixed-up imaging of various chest diseases
Session type:
Thematic Poster
Number:
3812
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Öner Balbay (Duzce, Turkey), Zeynep Burcin Yilmaz, Peri Meram Arbak, Tugçe Pasin, Esma Uslu, Ege Güleç Balbay, Öner Balbay. Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up. Eur Respir J 2016; 48: Suppl. 60, 3812
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
What if my lung-dominant connective tissue disease (LD-CTD) patient eventually met criteria for a definite CTD: The role of prognosis!
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27
Year: 2005
Usefulness of a myositis antibody immunoblot in diagnosis of connective tissue disease (CTD) related interstitial lung disease (ILD)
Source: International Congress 2014 – ILDs 4
Year: 2014
Prevalence of pulmonary involvement in rheumatoid arthritis patients in Indian population
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD)
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy.
Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases
Year: 2017
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Lung structure and function relation in systemic sclerosis: Application of lung densitometry
Source: International Congress 2015 – A more functional view of chest pathology
Year: 2015
Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Interstitial lung disease in a single center inception cohort of early rheumatoid arthritis patients
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Clinical manifestation and prognostic factor in anti-aminoacyl-tRNA synthetase autoantibodies-associated interstitial lung disease
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
LATE-BREAKING ABSTRACT: Erythropoietin (EPO) inhibits the immunohistochemical expression of Tumor Necrosis Factor-a (TNF-a) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats
Source: International Congress 2014 – Lung cell biology in injury and repair
Year: 2014
Chemical exposure triggering connective tissue disease with lung involvement
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
The effects of tobramycin on pulmonary fibroblast function
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Neoplasia in patients with ILD; shortened survival
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy},
Source: Eur Respir J 2012; 40: 641-648
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept